Bio-Synthesis Inc. Announces Exclusive Collaboration in the Area of Immune Agonists and Antagonists
Lewisville, TX, January 25, 2008 --(PR.com)-- Bio-Synthesis Inc., a closely held biotechnology company, is pleased to announce an exclusive scientific collaboration with Dr. Dante Marciani, a world renowned expert in immune agonists. Over the last 20 years, Dr. Marciani has pioneered work with proprietary immune stimulatory saponins and their semi-synthetic analogs that have immune enhancing activities. These small molecule constructs have the potential to stimulate Th1 immunity thus become an important element in preventive vaccines as well as active immunotherapy.
These plant-derived glycosides and their analogs have the unique ability to stimulate antigen-specific CTL production that will seek and destroy cells carrying abnormal markers, such as viral, intracellular parasites or tumor markers.
Previous work by Dr. Marciani has been effective in stimulating a protective preventive immune response in commercial products, against various pathogens, such as retroviruses. These molecules have the capacity to stimulate both humoral and cell-mediated immunity; its inclusion in vaccines may result in a safe and protective immune response against infection.
The collaboration between Dr. Marciani and BioSynthesis is focused on proprietary novel glycosides that stimulate innate immunity while taking advantage of the synergistic effects between innate and adaptive immunity. In addition, the collaboration extends to proprietary compounds that down regulate Th1 immunity, an area of significance in the treatment of chronic inflammatory conditions.
About Bio-Synthesis
Bio-Synthesis Inc, headquartered in Lewisville, is a closely held company that is a leader in providing integrated custom synthesis solutions for life science research worldwide. With a vision for innovation, Bio-Synthesis offers expertise in technologies from oligo synthesis such as DNA, RNA, LNA, PNA to peptides, antibody, organic synthesis and molecular reagents. BioSynthesis carries a broad line of chemical modifications, labelings, special synthesis, conjugations, arrays services and reagents for basic research, high-throughput screening and drug discovery. BSI’s staff of highly experienced and qualified chemists, biologists and immunologists has reliably and consistently provided products and services to large pharmaceuticals and universities across the country that meet the most demanding requirements for quality, turnaround and expert technical support.
For more information, please call Dr. Miguel Castro, BioSynthesis’ President and CEO, 1-800-227-0627 or visit www.biosyn.com.
###
These plant-derived glycosides and their analogs have the unique ability to stimulate antigen-specific CTL production that will seek and destroy cells carrying abnormal markers, such as viral, intracellular parasites or tumor markers.
Previous work by Dr. Marciani has been effective in stimulating a protective preventive immune response in commercial products, against various pathogens, such as retroviruses. These molecules have the capacity to stimulate both humoral and cell-mediated immunity; its inclusion in vaccines may result in a safe and protective immune response against infection.
The collaboration between Dr. Marciani and BioSynthesis is focused on proprietary novel glycosides that stimulate innate immunity while taking advantage of the synergistic effects between innate and adaptive immunity. In addition, the collaboration extends to proprietary compounds that down regulate Th1 immunity, an area of significance in the treatment of chronic inflammatory conditions.
About Bio-Synthesis
Bio-Synthesis Inc, headquartered in Lewisville, is a closely held company that is a leader in providing integrated custom synthesis solutions for life science research worldwide. With a vision for innovation, Bio-Synthesis offers expertise in technologies from oligo synthesis such as DNA, RNA, LNA, PNA to peptides, antibody, organic synthesis and molecular reagents. BioSynthesis carries a broad line of chemical modifications, labelings, special synthesis, conjugations, arrays services and reagents for basic research, high-throughput screening and drug discovery. BSI’s staff of highly experienced and qualified chemists, biologists and immunologists has reliably and consistently provided products and services to large pharmaceuticals and universities across the country that meet the most demanding requirements for quality, turnaround and expert technical support.
For more information, please call Dr. Miguel Castro, BioSynthesis’ President and CEO, 1-800-227-0627 or visit www.biosyn.com.
###
Contact
Bio-Synthesis Inc.
Angela Ragan
972-420-8505
www.biosyn.com
Angela Ragan
972-420-8505
www.biosyn.com
Contact
Categories